Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial

Autor: Dalong Zhu, Weimin Wang, Guoyu Tong, Guoqing Ma, Jianhua Ma, Jie Han, Xin Zhang, Yang Liu, Shenglian Gan, Hong Qin, Qing Zheng, Jing Ning, Zhiyi Zhu, Mengying Guo, Yue Bu, Yao Li, Catherine L. Jones, Martijn Fenaux, Mohammed K. Junaidi, Susan Xu, Hai Pan

Publikováno v: Nature Communications, Vol 15, Iss 1, Pp 1-11 (2024)

Abstract Glucagon-like peptide-1 (GLP-1) analogs are important therapeutics for type 2 diabetes and obesity. Ecnoglutide (XW003) is a novel, long-acting GLP-1 analog. We conducted a Phase 2, randomized, double-blind, placebo-controlled study enrollin

Externí odkaz: https://doaj.org/article/6fc9855574f143a59ad4763f2df3fad9

Nutritional perspectives on sickle cell disease in Africa: a systematic review

Autor: Eunice Berko Nartey, Jonathan Spector, Seth Adu-Afarwuah, Catherine L. Jones, Alan Jackson, Agartha Ohemeng, Rajiv Shah, Alice Koryo-Dabrah, Amma Benneh-Akwasi Kuma, Hyacinth I. Hyacinth, Matilda Steiner-Asiedu

Publikováno v: BMC Nutrition, Vol 7, Iss 1, Pp 1-21 (2021)

Abstract Background Sickle cell disease (SCD) is an inherited blood disorder that predominantly affects individuals in sub-Saharan Africa. However, research that elucidates links between SCD pathophysiology and nutritional status in African patients

Externí odkaz: https://doaj.org/article/932129c6fa8340de9877234fa71f188e

A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers

Autor: Catherine L. Jones, Surendra Machineni, Avantika Barve, Stephen Youngberg, Erin Brandt, Richard Colvin, Kristina Dabovic, Christopher T. Jones

Publikováno v: Journal of Drug Assessment

Objective: Infection with hepatitis C virus is the leading indication for liver transplantation and most common cause of infectious disease-related mortality in the United States. BZF961 is a novel inhibitor of the hepatitis C virus NS3-4A protease.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db9c5dea9be4497cf9079718b3641260
http://europepmc.org/articles/PMC6201795

Drug Discovery for Kinetoplastid Diseases : Future Directions

Autor: John M. Kelly, Phillip Scott, Rick L. Tarleton, Jonathan M. Spector, Catherine L. Jones, José Mengel, Jeremy C. Mottram, Claudio Gimpelewicz, Michael P. Barrett, Pascal Mäser, Christopher J. Faraday, David L. Sacks, Gerald F. Späth, Srinivasa P. S. Rao, Thierry T. Diagana, Glenn Dranoff, Asrat Hailu, Janis K. Lazdins-Helds, Charles E. Mowbray

Publikováno v: ACS Infectious Diseases
ACS Infectious Diseases, American Chemical Society, 2018, ⟨10.1021/acsinfecdis.8b00298⟩
ACS Infectious Diseases, 2018, ⟨10.1021/acsinfecdis.8b00298⟩

International audience; Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2eba2309dadb2c9c67d6eec1eb23ddf
https://eprints.whiterose.ac.uk/139513/1/Mottram_Rao_et_al_Kinetoplastid_Viewpoint_ACSID_proof.pdf

Hitting malaria where it hurts

Autor: Catherine L. Jones, Thierry T. Diagana

Publikováno v: Nature Microbiology. 2:1336-1337

The goal of malaria eradication is threatened by drug resistance. Now, two studies characterize Plasmodium falciparum PKG inhibitors and hexahydroquinolines as antimalarial compounds that could block transmission and help mitigate the risk of parasit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::04f689c275b940afc5de88d4b6c8fcb9
https://doi.org/10.1038/s41564-017-0036-z